Cancer Biology & Therapy
Volume 23, 2022 - Issue 1
Open access
5,128
Views
8
CrossRef citations to date
0
Altmetric
Research Article
Feasibility and safety of targeting mitochondria for cancer therapy – preclinical characterization of gamitrinib, a first-in-class, mitochondriaL-targeted small molecule Hsp90 inhibitor
Umar Hayata Pharmaceutical Advisors, LLC, Princeton, USAView further author information
, Gary T. Elliottb Galenic Strategies Inc, WindsorView further author information
, Anthony J. Olszanskic Phase 1 Developmental Therapeutics Program, Department of Hematology/Oncology Fox Chase Cancer Center, PhiladelphiaView further author information
& Dario C. Altierid Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, USACorrespondence[email protected]
View further author information
View further author information
Pages 117-126
|
Received 22 Oct 2021, Accepted 10 Jan 2022, Published online: 06 Feb 2022
Reprints and Permissions
This is an open access article distributed under the terms of the Creative Commons CC BY license, which permits unrestricted use, distribution, reproduction in any medium, provided the original work is properly cited.
You are not required to obtain permission to reuse this article in part or whole.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.